ANZLG HD3/TROG 99.01 - Hodgkins Disease IFRT - HD3

By w.paterson
August 14, 2021
0 Comments

An ANZLG / TROG Prospective Study of Limited Chemotherapy and Involved Field Radiotherapy for Patients With Clinical Stage I-II Hodgkin’s Disease

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

October 18, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

September 6, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing

Join us to raise $25,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

An ANZLG / TROG Prospective Study of Limited Chemotherapy and Involved Field Radiotherapy for Patients With Clinical Stage I-II Hodgkin’s Disease

TROG 99.02 – Anal Canal

TROG 98.06 – Oesophagus

Related Post

NINJA Radiation Therapy Trial participant tells his journey to treatment

The gift that kept on giving

Join us to raise $25,000

ANZLG HD3/TROG 99.01 – Hodgkins Disease IFRT – HD3

An ANZLG / TROG Prospective Study of Limited Chemotherapy and Involved Field Radiotherapy for Patients With Clinical Stage I-II Hodgkin’s Disease

TROG 99.02 – Anal Canal

TROG 98.06 – Oesophagus

Related Post

NINJA Radiation Therapy Trial participant tells his journey to treatment

The gift that kept on giving

Join us to raise $25,000